Login
Toggle sidebar

Lint: squamous-cell-carcinoma-of-the-lung

squamous-cell-carcinoma-of-the-lung
Acronyms
warning

"Different types of NSCLC respond differently to biological agents. High expression of EGFR in some squamous cell carcinoma patients may benefit from cetuximab (monoclonal antibody against EGFR). However, lung squamous cell carcinoma patients receiving bevacizumab (monoclonal antibody against VEGF) have a high incidence of pulmonary haemorrhage, thus it is only used for non-squamous cell carcinoma NSCLC 7."

Line 44:90 · 'EGFR' has no definition. Spell it out if it's unfamiliar to the audience.

"Different types of NSCLC respond differently to biological agents. High expression of EGFR in some squamous cell carcinoma patients may benefit from cetuximab (monoclonal antibody against EGFR). However, lung squamous cell carcinoma patients receiving bevacizumab (monoclonal antibody against VEGF) have a high incidence of pulmonary haemorrhage, thus it is only used for non-squamous cell carcinoma NSCLC 7."

Line 44:192 · 'EGFR' has no definition. Spell it out if it's unfamiliar to the audience.
Inline EG
suggestion

"Metastatic disease may be the first sign of malignancy (e.g. cerebral metastasis, pathological fracture, etc)."

Line 12:59 · Consider replacing a bracketed e.g. with an inline e.g. after a comma.
Links
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
14
5
0
0
0
0
0
0
0
6
7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0